The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo
administered in addition to standard therapy. Following the baseline visit, subjects will be
expected to return for clinic visits at 1 month, 3 months, and every 6 months until the end
of the study. Average time in the study for an individual subject is expected to be about 3
years.

Inclusion Criteria:

- Men or women at least 18 years old. Women must be post-menopausal or using a highly
effective method for avoidance of pregnancy.

- Current treatment with statin therapy unless the study doctor determines statins are
not appropriate for the subject.

- Chronic coronary heart disease

- At least one of the following:

- At least 60 years old

- Diabetes requiring treatment with medication

- Low HDL cholesterol ("good cholesterol")

- Currently smoke cigarettes or stopped smoking within the past 3 months

- Diagnosed mild or moderate reduction in kidney function

- Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months
prior to study entry) OR peripheral arterial disease.

Exclusion Criteria:

- Planned coronary revascularization (such as stent placement or heart bypass) or any
other major surgical procedure.

- Liver disease

- Severe reduction in kidney function OR removal of a kidney OR kidney transplant

- Severe heart failure

- Blood pressure higher than normal despite lifestyle changes and treatment with
medications

- Any life-threatening disease expected to result in death within the next 2 years
(other than heart disease)

- Severe asthma that is poorly controlled with medication

- Pregnant (Note: A pregnancy test will be performed on all non-sterile women prior to
study entry)

- Previous severe allergic response to food, drink, insect stings, etc.

- Drug or alcohol abuse within the past 6 months OR mental/psychological impairment
that may prevent the subject from complying with study procedures or understanding
the goal and potential risks of participating in the study.

- Certain medications that may interfere with the study medication (these will be
identified by the study doctor)

- Participation in a study of an investigational medication within the past 30 days

- Current participation in a study of an investigational device